The issue has been acknowledged by China's government - the country's 2013 Mental Health Law aimed to stop this abuse, making ...

Johnson & Johnson is starting the year off strong with a $14.6 billion acquisition of the biopharma firm Intra-Cellular Therapies — best known for its blockbuster drug Caplyta. The deal was announced ...

And GSK said it would pay up to $1.15 billion privately-held IDRx, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of GIST, which stands for Gastrointestinal ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression ...

In “More or Less Maddy,” Genova said she hopes to make people more aware of bipolar disease: the forms it takes (bipolar 2, a less severe condition with hypomania only or bipolar 1 that ...

Beloved TV star Madchen Amick has been talking about navigating her son Sly’s Bipolar 1 diagnosis together, and how in 2025, he’s getting a lot better! Amick has truly been a supportive mom throughout ...

He caught it really fast, and they changed that medication immediately and they ... Sly was diagnosed with Bipolar 1 back in 2023 after years of searching for a diagnosis. It started after a ...

Trusted by U.S. Physicians and Pharmacies and Available Nationwide. Take Control of Your Weight Loss Journey: How Does GLP-1 Medication Work? GLP-1 (Glucagon-like peptide-1) medications are a class of ...

The findings highlight how the integration of glucagon-like peptide-1 (GLP-1) medications for weight loss is reshaping the Aesthetics market, fueling significant growth for practices across the ...

Medications for myasthenia gravis (MG) can include cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, and antibody fragment medications. While myasthenia gravis ...